Epithelioid Sarcoma Market
DelveInsight's "Epithelioid Sarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Epithelioid Sarcoma, historical and forecasted epidemiology as well as the Epithelioid Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Epithelioid Sarcoma market report provides current treatment practices, emerging drugs, Epithelioid Sarcoma market share of the individual therapies, current and forecasted Epithelioid Sarcoma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Epithelioid Sarcoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Epithelioid Sarcoma market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
Epithelioid Sarcoma Disease Understanding and Treatment Algorithm
Epithelioid sarcoma is a rare and slow-growing soft tissue cancer. The majority of cases begin in the soft tissue beneath the skin of a finger, hand, forearm, lower leg, or foot, however it can originate elsewhere on the body.
Epithelioid sarcoma often begins as a small firm single growth or lump that is painless, but several growths may emerge by the time a person seeks medical attention. Sarcomas can sometimes appear as ulcers that do not heal, like open wounds over the growths.
The typical form of epithelioid sarcoma (distal-type) primarily affects teens and young adults. A less common variant, known as large-cell (proximal-type) epithelioid sarcoma, is more aggressive and primarily affects adults.
Epithelioid sarcoma can be difficult to diagnose since it might be mistaken for other conditions with similar symptoms. For example, a skin ulcer that isn't healing might be misdiagnosed as a skin infection.
Surgery is the most common treatment for epithelioid sarcoma, however other therapies may be employed, such as
- Radiation therapy
- Chemotherapy
- Clinical Trials
Epithelioid Sarcoma Diagnosis
This segment of the report covers the detailed diagnostic methods or tests for Epithelioid Sarcoma.
The following tests and techniques are used to diagnose epithelioid:
- Imaging techniques such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET)
- Biopsy
Epithelioid Sarcoma Treatment
It covers the details of conventional and current medical therapies available in the Epithelioid Sarcoma market for the treatment of the condition. It also provides Epithelioid Sarcoma treatment algorithms and guidelines in the United States, Europe, and Japan.
Epithelioid Sarcoma Epidemiology
The Epithelioid Sarcoma epidemiology section provides insights about the historical and current Epithelioid Sarcoma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Epithelioid Sarcoma market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Epithelioid Sarcoma epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
- Epithelioid sarcomas are rare, and account for less than 1% of soft tissue sarcomas.
- Men are twice more likely to develop Epithelioid Sarcomas as compared to women.
Country Wise- Epithelioid Sarcoma Epidemiology
The epidemiology segment also provides the Epithelioid Sarcoma epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Epithelioid Sarcoma Drug Chapters
The drug chapter segment of the Epithelioid Sarcoma report encloses the detailed analysis of Epithelioid Sarcoma marketed drugs and late-stage (Phase-III and Phase-II) Epithelioid Sarcoma pipeline drugs. It also helps to understand the Epithelioid Sarcoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Epithelioid Sarcoma Marketed Drugs
The report provides the details of the marketed products/off-label treatments available for Epithelioid Sarcoma treatment.
Key Epithelioid Sarcoma Companies
- Epizyme, Inc.
- Bristol-Myers Squibb
- Amgen
- Merck Sharp & Dohme Corp.
- Sarcoma Oncology Research Center, LLC
- Aadi, LLC
Epithelioid Sarcoma Pipeline drugs
- Tazemetostat
- Doxorubicin HCl
- Talimogene Laherparepvec (T-VEC)
- Pembrolizumab
- Dasatinib
- Nab-Rapamycin
- Nivolumab
Epithelioid Sarcoma Market Outlook
The Epithelioid Sarcoma market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Epithelioid Sarcoma market trends by analyzing the impact of current Epithelioid Sarcoma therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Epithelioid Sarcoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Epithelioid Sarcoma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Epithelioid Sarcoma market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Findings
This section includes a glimpse of the Epithelioid Sarcoma market in 7MM.
The United States Epithelioid Sarcoma Market Outlook
This section provides the total Epithelioid Sarcoma market size and market size by therapies in the United States.
EU-5 Countries: Epithelioid Sarcoma Market Outlook
The total Epithelioid Sarcoma market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Epithelioid Sarcoma Market Outlook
The total Epithelioid Sarcoma market size and market size by therapies in Japan is also mentioned.
Epithelioid Sarcoma Drugs Uptake
This section focuses on the rate of uptake of the potential Epithelioid Sarcoma drugs recently launched in the Epithelioid Sarcoma market or expected to get launched in the market during the study period 2019-2032. The analysis covers Epithelioid Sarcoma market uptake by drugs; patient uptake by therapies; and sales of each drug.
Epithelioid Sarcoma Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Epithelioid Sarcoma market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Epithelioid Sarcoma Pipeline Development Activities
The Epithelioid Sarcoma report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Epithelioid Sarcoma key players involved in developing targeted therapeutics.
Pipeline Development Activities
The Epithelioid Sarcoma report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Epithelioid Sarcoma emerging therapies.
Reimbursement Scenario in Epithelioid Sarcoma
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current Epithelioid Sarcoma market trends, we take KOLs and SMEs ' opinion working in the Epithelioid Sarcoma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Epithelioid Sarcoma market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Epithelioid Sarcoma Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Epithelioid Sarcoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Epithelioid Sarcoma epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Epithelioid Sarcoma is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the Epithelioid Sarcoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Epithelioid Sarcoma market
Report Highlights
- In the coming years, the Epithelioid Sarcoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Epithelioid Sarcoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Epithelioid Sarcoma. The launch of emerging therapies will significantly impact the Epithelioid Sarcoma market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Epithelioid Sarcoma
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Epithelioid Sarcoma Report Insights
- Epithelioid Sarcoma Patient Population
- Therapeutic Approaches
- Epithelioid Sarcoma Pipeline Analysis
- Epithelioid Sarcoma Market Size and Trends
- Epithelioid Sarcoma Market Opportunities
- Impact of upcoming Epithelioid Sarcoma Therapies
Epithelioid Sarcoma Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Epithelioid Sarcoma Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Epithelioid Sarcoma Market
- Drugs Uptake
Epithelioid Sarcoma Report Assessment
- Current Treatment Practices
- Unmet Needs
- Epithelioid Sarcoma Pipeline Product Profiles
- Epithelioid Sarcoma Market Attractiveness
- Epithelioid Sarcoma Market Drivers
- Epithelioid Sarcoma Market Barriers
Key Questions
Epithelioid Sarcoma Market Insights:
- What was the Epithelioid Sarcoma drug class share (%) distribution in 2019 and how it would look like in 2032?
- What would be the Epithelioid Sarcoma total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
- What are the key findings pertaining to the market across 7MM and which country will have the largest Epithelioid Sarcoma market size during the forecast period (2019-2032)?
- At what CAGR, the Epithelioid Sarcoma market is expected to grow by 7MM during the forecast period (2019-2032)?
- What would be the Epithelioid Sarcoma market outlook across the 7MM during the forecast period (2019-2032)?
- What would be the Epithelioid Sarcoma market growth till 2032, and what will be the resultant market Size in the year 2032?
- How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?
Epithelioid Sarcoma Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of the Epithelioid Sarcoma?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical Epithelioid Sarcoma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Epithelioid Sarcoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Epithelioid Sarcoma?
- Out of all 7MM countries, which country would have the highest prevalent population of Epithelioid Sarcoma during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the Epithelioid Sarcoma treatment in addition to the approved therapies?
- What are the current treatment guidelines for the treatment of Epithelioid Sarcoma in the USA, Europe, and Japan?
- What are the Epithelioid Sarcoma marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Epithelioid Sarcoma?
- How many therapies are in-development by each company for Epithelioid Sarcoma treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Epithelioid Sarcoma treatment?
- What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Epithelioid Sarcoma therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Epithelioid Sarcoma and their status?
- What are the current challenges faced in drug development?
- What are the key designations that have been granted for the emerging therapies for Epithelioid Sarcoma?
- What are the global historical and forecasted market of Epithelioid Sarcoma?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Epithelioid Sarcoma market
- To understand the future market competition in the Epithelioid Sarcoma market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Epithelioid Sarcoma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Epithelioid Sarcoma market
- To understand the future market competition in the Epithelioid Sarcoma market
1. Key Insights
2. Executive Summary of Epithelioid Sarcoma
3. Competitive Intelligence Analysis for Epithelioid Sarcoma
4. Epithelioid Sarcoma: Market Overview at a Glance
4.1. Epithelioid Sarcoma Total Market Share (%) Distribution in 2019
4.2. Epithelioid Sarcoma Total Market Share (%) Distribution in 2032
5. Epithelioid Sarcoma: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Epithelioid Sarcoma Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Epithelioid Sarcoma Epidemiology Scenario in the 7MM (2019-2032)
7.4. United States Epidemiology
7.4.1. Epithelioid Sarcoma Epidemiology Scenario in the United States (2019-2032)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Epithelioid Sarcoma Epidemiology Scenario in Germany (2019-2032)
7.5.2. France Epidemiology
7.5.2.1. Epithelioid Sarcoma Epidemiology Scenario in France (2019-2032)
7.5.3. Italy Epidemiology
7.5.3.1. Epithelioid Sarcoma Epidemiology Scenario in Italy (2019-2032)
7.5.4. Spain Epidemiology
7.5.4.1. Epithelioid Sarcoma Epidemiology Scenario in Spain (2019-2032)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Epithelioid Sarcoma Epidemiology Scenario in the United Kingdom (2019-2032)
7.5.6. Japan Epidemiology
7.5.6.1. Epithelioid Sarcoma Epidemiology Scenario in Japan (2019-2032)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Epithelioid Sarcoma Treatment and Management
8.2. Epithelioid Sarcoma Treatment Algorithm
9. Epithelioid Sarcoma Unmet Needs
10. Key Endpoints of Epithelioid Sarcoma Treatment
11. Epithelioid Sarcoma Marketed Products
11.1. List of Epithelioid Sarcoma Marketed Drugs in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Epithelioid Sarcoma Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Epithelioid Sarcoma: Seven Major Market Analysis
13.1. Key Findings
13.2. Epithelioid Sarcoma Market Size in 7MM
13.3. Epithelioid Sarcoma Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Epithelioid Sarcoma Market Outlook
15.1. United States: Epithelioid Sarcoma Market Size
15.1.1. Total Epithelioid Sarcoma Market Size in the United States
15.1.2. Epithelioid Sarcoma Market Size by Therapies in the United States
15.2. EU-5 countries: Epithelioid Sarcoma Market Size and Outlook
15.3. Germany: Epithelioid Sarcoma Market Size
15.3.1. Epithelioid Sarcoma Total Market Size in Germany
15.3.2. Epithelioid Sarcoma Market Size by Therapies in Germany
15.4. France: Epithelioid Sarcoma Market Size
15.4.1. Epithelioid Sarcoma Total Market Size in France
15.4.2. Epithelioid Sarcoma Market Size by Therapies in France
15.5. Italy: Epithelioid Sarcoma Market Size
15.5.1. Epithelioid Sarcoma Total Market Size in Italy
15.5.2. Epithelioid Sarcoma Market Size by Therapies in Italy
15.6. Spain: Epithelioid Sarcoma Market Size
15.6.1. Epithelioid Sarcoma Total Market Size in Spain
15.6.2. Epithelioid Sarcoma Market Size by Therapies in Spain
15.7. United Kingdom: Epithelioid Sarcoma Market Size
15.7.1. Epithelioid Sarcoma Total Market Size in the United Kingdom
15.7.2. Epithelioid Sarcoma Market Size by Therapies in the United Kingdom
15.8. Japan: Epithelioid Sarcoma Market Outlook
15.8.1. Japan Epithelioid Sarcoma Market Size
15.8.2. Epithelioid Sarcoma Total Market Size in Japan
15.8.3. Epithelioid Sarcoma Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Epithelioid Sarcoma
17. KOL Views
18. Epithelioid Sarcoma Market Drivers
19. Epithelioid Sarcoma Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
*The table of contents is not exhaustive; the final content may vary.
List of Table
Table 1: 7MM Epithelioid Sarcoma Epidemiology (2019-2032)
Table 2: 7MM Epithelioid Sarcoma Diagnosed and Treatable Cases (2019-2032)
Table 3: Epithelioid Sarcoma Epidemiology in the United States (2019-2032)
Table 4: Epithelioid Sarcoma Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Epithelioid Sarcoma Epidemiology in Germany (2019-2032)
Table 6: Epithelioid Sarcoma Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Epithelioid Sarcoma Epidemiology in France (2019-2032)
Table 8: Epithelioid Sarcoma Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Epithelioid Sarcoma Epidemiology in Italy (2019-2032)
Table 10: Epithelioid Sarcoma Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Epithelioid Sarcoma Epidemiology in Spain (2019-2032)
Table 12: Epithelioid Sarcoma Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Epithelioid Sarcoma Epidemiology in the UK (2019-2032)
Table 14: Epithelioid Sarcoma Diagnosed and Treatable Cases in the UK (2019-2032)
Table 15: Epithelioid Sarcoma Epidemiology in Japan (2019-2032)
Table 16: Epithelioid Sarcoma Diagnosed and Treatable Cases in Japan (2019-2032)
Table 17: Drug Name, Clinical Trials by Recruitment status
Table 18: Drug Name, Clinical Trials by Zone
Table 19: Total Seven Major Market Size in USD, Million (2019-2032)
Table 20: Region-wise Market Size in USD, Million (2019-2032)
Table 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)
Table 22: United States Market Size in USD, Million (2019-2032)
Table 23: United States Market Size by Therapy in USD, Million (2019-2032)
Table 24: Germany Market Size in USD, Million (2019-2032)
Table 25: Germany Market Size by Therapy in USD, Million (2019-2032)
Table 26: France Market Size in USD, Million (2019-2032)
Table 27: France Market Size by Therapy in USD, Million (2019-2032)
Table 28: Italy Market Size in USD, Million (2019-2032)
Table 29: Italy Market Size by Therapy in USD, Million (2019-2032)
Table 30: Spain Market Size in USD, Million (2019-2032)
Table 31: Spain Market Size by Therapy in USD, Million (2019-2032)
Table 32: United Kingdom Market Size in USD, Million (2019-2032)
Table 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)
Table 34: Japan Market Size in USD, Million (2019-2032)
Table 35: Japan Market Size by Therapy in USD, Million (2019-2032)
*The list of tables is not exhaustive; the final content may vary
List of Figures
Figure 1: 7MM Epithelioid Sarcoma Epidemiology (2019-2032)
Figure 2: 7MM Epithelioid Sarcoma Diagnosed and Treatable Cases (2019-2032)
Figure 3: Epithelioid Sarcoma Epidemiology in the United States (2019-2032)
Figure 4: Epithelioid Sarcoma Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5: Epithelioid Sarcoma Epidemiology in Germany (2019-2032)
Figure 6: Epithelioid Sarcoma Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7: Epithelioid Sarcoma Epidemiology in France (2019-2032)
Figure 8: Epithelioid Sarcoma Diagnosed and Treatable Cases in France (2019-2032)
Figure 9: Epithelioid Sarcoma Epidemiology in Italy (2019-2032)
Figure 10: Epithelioid Sarcoma Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11: Epithelioid Sarcoma Epidemiology in Spain (2019-2032)
Figure 12: Epithelioid Sarcoma Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13: Epithelioid Sarcoma Epidemiology in the UK (2019-2032)
Figure 14: Epithelioid Sarcoma Diagnosed and Treatable Cases in the UK (2019-2032)
Figure 15: Epithelioid Sarcoma Epidemiology in Japan (2019-2032)
Figure 16: Epithelioid Sarcoma Diagnosed and Treatable Cases in Japan (2019-2032)
Figure 17: Drug Name, Clinical Trials by Recruitment status
Figure 18: Drug Name, Clinical Trials by Zone
Figure 19: Total Seven Major Market Size in USD, Million (2019-2032)
Figure 20: Region-wise Market Size in USD, Million (2019-2032)
Figure 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)
Figure 22: United States Market Size in USD, Million (2019-2032)
Figure 23: United States Market Size by Therapy in USD, Million (2019-2032)
Figure 24: Germany Market Size in USD, Million (2019-2032)
Figure 25: Germany Market Size by Therapy in USD, Million (2019-2032)
Figure 26: France Market Size in USD, Million (2019-2032)
Figure 27: France Market Size by Therapy in USD, Million (2019-2032)
Figure 28: Italy Market Size in USD, Million (2019-2032)
Figure 29: Italy Market Size by Therapy in USD, Million (2019-2032)
Figure 30: Spain Market Size in USD, Million (2019-2032)
Figure 31: Spain Market Size by Therapy in USD, Million (2019-2032)
Figure 32: United Kingdom Market Size in USD, Million (2019-2032)
Figure 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)
Figure 34: Japan Market Size in USD, Million (2019-2032)
Figure 35: Japan Market Size by Therapy in USD, Million (2019-2032)
*The list of figures is not exhaustive; the final content may vary
- Epizyme, Inc.
- Bristol-Myers Squibb
- Amgen
- Merck Sharp & Dohme Corp.
- Sarcoma Oncology Research Center, LLC
- Aadi, LLC